Skip to main content

Table 2 Concomitant mood stabilizers

From: Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments

Mood stabilizer at baseline, n (%) Placebo n = 199 Armodafinil 150 mg/day n = 200
Patients taking one mood stabilizer 150 (75) 158 (79)
 Aripiprazole 16 (8) 9 (5)
 Lamotrigine 26 (13) 28 (14)
 Lithium 12 (6) 18 (9)
 Olanzapine 23 (12) 25 (13)
 Quetiapine 18 (9) 26 (13)
 Risperidone 29 (15) 24 (12)
 Valproic acid 26 (13) 28 (14)
Patients taking two mood stabilizers 45 (23) 38 (19)
 Aripiprazole + lamotrigine 4 (2) 1 (<1)
 Lamotrigine + quetiapine 7 (4) 1 (<1)
 Lamotrigine + ziprasidone 1 (<1) 1 (<1)
 Lithium + aripiprazole 1 (<1) 0
 Lithium + lamotrigine 3 (2) 2 (1)
 Lithium + olanzapine 2 (1) 0
 Lithium + quetiapine 4 (2) 3 (2)
 Lithium + risperidone 1 (<1) 1 (<1)
 Lithium + valproic acid 2 (1) 1 (<1)
 Lithium + ziprasidone 3 (2) 1 (<1)
 Olanzapine + lamotrigine 1 (<1) 1 (<1)
 Olanzapine + quetiapine 1 (<1) 0
 Valproic acid + aripiprazole 0 2 (1)
 Valproic acid + lamotrigine 2 (1) 0
 Valproic acid + olanzapine 5 (3) 8 (4)
 Valproic acid + quetiapine 5 (3) 9 (5)
 Valproic acid + risperidone 3 (2) 5 (3)
 Valproic acid + ziprasidone 0 2 (1)
Patients taking three mood stabilizers 1 (<1) 3 (2)
 Lithium + lamotrigine + ziprasidone 0 1 (<1)
 Valproic acid + aripiprazole + risperidone 0 1 (<1)
 Valproic acid + olanzapine + lamotrigine 0 1 (<1)
 Valproic acid + risperidone + quetiapine 1 (<1) 0
Patients with mood stabilizer unknown 3 (2) 1 (<1)